Drug intelligence / Profile preview

libivirumab

Development stage: Unknown
Lead developer: Vaxart
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Libivirumab is a human monoclonal antibody targeting the hepatitis B virus (HBV), specifically directed against the large envelope protein (L-HBsAg) of HBV. It has been tested in vitro for neutralization of HBV, demonstrating IC50 values in the nanomolar range. Libivirumab has been studied both alone and as part of the investigational combination HepeX-B (with exbivirumab) for hepatitis B prophylaxis and therapy. Its principal mechanism is the neutralization of HBV particles, preventing cellular infection[2][10].

Brand names: HepeX-B (as combination with exbivirumab)
Other names: libivirumab

Targets

HBsAg (Hepatitis B surface antigen)

Beyond the preview

Go deeper on libivirumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on libivirumab.

Explore the full profile